Post by Lonza

What does it take to turn scientific ambition into scalable gene therapy manufacturing? In our latest R&D Blog, Bingnan Gu, PhD, MBA, Senior Director, R&D, Viral Vector and Cell Therapy and Vijetha Bhat, Manager, Research & Development, share a decade-long journey of advancing AAV producer cell line technology which is shaped by persistence, scientific iteration, and collaboration across disciplines. From early challenges and strategic pivots to achieving high-performing, scalable systems, this work reflects our ongoing commitment to enabling more consistent and cost-effective viral vector manufacturing. By integrating key elements into the cell line, this platform has the potential to simplify production and help bring gene therapies closer to more patients. Read the full story: https://ow.ly/gzAz50Zl3HN #Lonza #CellAndGene #GeneTherapy #Innovation #RDBlog